| [1] |
Khwaja A, Bjorkholm M, Gale RE,et al. Acute myeloid leukaemia[J]. Nat Rev Dis Primers, 2016, 2: 16010. doi: 10.1038/nrdp.2016.10.
|
| [2] |
Achyutuni S, Xu J. Targeting an AML-sustaining metabolic node[J]. Blood, 2025, 145: 1341-1343.
|
| [3] |
Wang E, Lu SX, Pastore A,et al. Targeting an RNA-binding protein network in acute myeloid leukemia[J]. Cancer Cell, 2019, 35: 369-384.e367.
|
| [4] |
Vujovic A, de Rooij L, Chahi AK,et al. In vivo screening unveils pervasive RNA-binding protein dependencies in leukemic stem cells and identifies ELAVL1 as a therapeutic target[J]. Blood Cancer Discov, 2023, 4: 180-207.
|
| [5] |
Figueroa ME, Abdel-Wahab O, Lu C,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation[J]. Cancer Cell, 2010, 18: 553-567.
|
| [6] |
Liu Y, Xu W, Li M,et al. The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer[J]. Acta Pharm Sin B, 2023, 13: 1438-1466.
|
| [7] |
Xiang S, Gu H, Jin L,et al. LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect[J]. Proc Natl Acad Sci U S A, 2018, 115: E1465-e1474.
|
| [8] |
Castello A, Fischer B, Eichelbaum K,et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins[J]. Cell, 2012, 149: 1393-1406.
|
| [9] |
Cook KB, Kazan H, Zuberi K,et al. RBPDB: a database of RNA-binding specificities[J]. Nucleic Acids Res, 2011, 39: 301-308.
|
| [10] |
Wingelhofer B, Somervaille TCP. Emerging epigenetic therapeutic targets in acute myeloid leukemia[J]. Front Oncol, 2019, 9: 850. doi: 10.3389/fonc.2019.00850.
|
| [11] |
Dong XY, Li YL, Jiang L,et al. Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia[J]. 中华医学杂志, 2019, 40: 40-45.
|
| [12] |
Qin T, Cheng Y, Wang X. RNA-binding proteins as drivers of AML and novel therapeutic targets[J]. Leuk Lymphoma, 2022, 63: 1045-1057.
|